skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Ridaforolimus (Code C49061)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ridaforolimus

Definition: A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.

NCI-GLOSS Definition: A substance being studied in the treatment of soft tissue and bone cancers. It is also being studied in the treatment of other solid tumors and hematologic cancer. Ridaforolimus stops cells from dividing and may cause cancer cells to die. It is a type of mTOR inhibitor.

Display Name: Ridaforolimus

Label: Ridaforolimus

NCI Thesaurus Code: C49061 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2713007  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Rapamycin, 42-(dimethylphosphinate)

External Source Codes: 
CAS Registry Number 572924-54-0 (see NLM ChemIDplus info)
FDA UNII Code 48Z35KB15K
PDQ Closed Trial Search ID 354223
PDQ Open Trial Search ID 354223 (check for NCI PDQ open clinical trial info)
UMLS CUI C2713007

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C53H84NO14P
code C49061
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name AP23573
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom